TY - JOUR
T1 - Treatment preferences in men with erectile dysfunction
T2 - An open label study in Korean men switching from sildenafil citrate to tadalafil
AU - Ahn, Tai Young
AU - Lee, Sung Won
AU - Kim, Sae Woong
AU - Yang, Dae Yul
AU - Park, Nam Cheol
AU - Min, Kweon Sik
AU - Park, Kwangsung
AU - Paick, Jae Seung
AU - Dyachkova, Yulia
AU - Dwight, Trisha
AU - Lee, Myung Sea Luke
PY - 2007/11
Y1 - 2007/11
N2 - Aim: To evaluate patient preferences for sildenafil citrate or tadalafil (PDE-5 inhibitors available for the treatment of erectile dysfunction [ED]) and assess potential reasons for these preferences. Methods: Thisopen-label study was conducted on Korean men taking sildenafil, at least 6 weeks prior to study entry, for ED. Following screening, patients continued sildenafil treatment for 4 weeks, then after a 1-week washout period, switched to tadalafil for 8 weeks. Patients then continued with their treatment of choice during an extension phase. Psychosocial factors (time concern, spontaneity, sexual self-confidence) were evaluated using Psychological and Interpersonal Relationship Scales (PAIRS), while timing of dose to sexual attempt patterns were assessed from patient diaries. Results: The present studyenrolled 160 Korean men (mean age 55 years) with prior median sildenafil use of 585 days. During the extension phase, 73.7% of patients elected to take tadalafil, whereas 26.3% chose sildenafil (P < 0.001). After switching from sildenafil to tadalafil, mean PAIRS time concern scores decreased from 2.54 to 2.42 (P = 0.002), with no statistically significant differences observed between the sildenafil and tadalafil assessment phases in sexual spontaneity and self-confidence scores. Sexual attempts made > 4 h to ≤ 36 h post-dose occurred in 4.5% of patients during the sildenafil assessment phase compared with 17.5% during the tadalafil assessment phase. Conclusion: After experiencing both sildenafil and tadalafil, the majority of patients exhibited a preference for tadalafil. This preference might be influenced by psychosocial factors, such as decreased time concerns, and a broader window of opportunity available for sexual activity.
AB - Aim: To evaluate patient preferences for sildenafil citrate or tadalafil (PDE-5 inhibitors available for the treatment of erectile dysfunction [ED]) and assess potential reasons for these preferences. Methods: Thisopen-label study was conducted on Korean men taking sildenafil, at least 6 weeks prior to study entry, for ED. Following screening, patients continued sildenafil treatment for 4 weeks, then after a 1-week washout period, switched to tadalafil for 8 weeks. Patients then continued with their treatment of choice during an extension phase. Psychosocial factors (time concern, spontaneity, sexual self-confidence) were evaluated using Psychological and Interpersonal Relationship Scales (PAIRS), while timing of dose to sexual attempt patterns were assessed from patient diaries. Results: The present studyenrolled 160 Korean men (mean age 55 years) with prior median sildenafil use of 585 days. During the extension phase, 73.7% of patients elected to take tadalafil, whereas 26.3% chose sildenafil (P < 0.001). After switching from sildenafil to tadalafil, mean PAIRS time concern scores decreased from 2.54 to 2.42 (P = 0.002), with no statistically significant differences observed between the sildenafil and tadalafil assessment phases in sexual spontaneity and self-confidence scores. Sexual attempts made > 4 h to ≤ 36 h post-dose occurred in 4.5% of patients during the sildenafil assessment phase compared with 17.5% during the tadalafil assessment phase. Conclusion: After experiencing both sildenafil and tadalafil, the majority of patients exhibited a preference for tadalafil. This preference might be influenced by psychosocial factors, such as decreased time concerns, and a broader window of opportunity available for sexual activity.
KW - Erectile dysfunction
KW - Preference
KW - Psychological and Interpersonal Relationship Scales
KW - Sildenafil citrate
KW - Tadalafil
UR - https://www.scopus.com/pages/publications/36048946301
U2 - 10.1111/j.1745-7262.2007.00319.x
DO - 10.1111/j.1745-7262.2007.00319.x
M3 - Article
C2 - 17968461
AN - SCOPUS:36048946301
SN - 1008-682X
VL - 9
SP - 760
EP - 770
JO - Asian Journal of Andrology
JF - Asian Journal of Andrology
IS - 6
ER -